BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25776793)

  • 1. [Chronic lymphocytic leukemia : treatment concepts in transition].
    Eichhorst B; Hallek M
    Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial therapy of chronic lymphocytic leukemia.
    Eichhorst B; Cramer P; Hallek M
    Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of chronic lymphocytic leukemia.
    Stilgenbauer S; Furman RR; Zent CS
    Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
    Cramer P; Hallek M; Eichhorst B
    Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
    D'Souza P; Walker G
    Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
    Shvidel L; Berrebi A
    Expert Rev Hematol; 2016 Mar; 9(3):245-54. PubMed ID: 26613391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern concepts in the treatment of chronic lymphocytic leukemia.
    Smolej L
    Hematology; 2009 Oct; 14(5):249-54. PubMed ID: 19843378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ultra high risk chronic lymphocytic leukemia -  characteristics and treatment options].
    Lysák D; Jindra P
    Vnitr Lek; 2013 Oct; 59(10):887-94. PubMed ID: 24164366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
    Tausch E; Mertens D; Stilgenbauer S
    Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?
    Dreger P; Montserrat E; ;
    Curr Hematol Malig Rep; 2015 Mar; 10(1):59-64. PubMed ID: 25651976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the optimal initial treatment for chronic lymphocytic leukemia?
    Lin TS
    Oncology (Williston Park); 2007 Dec; 21(14):1641-9; discussion 1649-54, 1659, 1662. PubMed ID: 18247015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.